The complex pathophysiology of allergic rhinitis: Scientific rationale for the development of an alternative treatment option

Forskningsoutput: TidskriftsbidragÖversiktsartikel

Standard

The complex pathophysiology of allergic rhinitis : Scientific rationale for the development of an alternative treatment option. / Bjermer, Leif; Westman, Marit; Holmström, Mats; Wickman, Magnus C.

I: Allergy, Asthma and Clinical Immunology, Vol. 15, Nr. 1, 24, 16.04.2019.

Forskningsoutput: TidskriftsbidragÖversiktsartikel

Harvard

APA

CBE

MLA

Vancouver

Author

RIS

TY - JOUR

T1 - The complex pathophysiology of allergic rhinitis

T2 - Allergy, Asthma and Clinical Immunology

AU - Bjermer, Leif

AU - Westman, Marit

AU - Holmström, Mats

AU - Wickman, Magnus C.

PY - 2019/4/16

Y1 - 2019/4/16

N2 - Allergic rhinitis (AR) poses a global health problem and can be challenging to treat. Many of the current symptomatic treatments for AR have been available for decades, yet there has been little improvement in patient quality of life or symptom burden over the years. In this review, we ask why this might be and explore the pathophysiological gaps that exist within the various AR treatment classes. We focus on the benefits and drawbacks of different treatment options and delivery routes for AR treatments and consider how, given what is known about AR pathophysiology and symptomatology, patients may be offered more effective treatment options for rapid, effective, and sustained AR control. In particular, we consider how a new AR preparation, MP-AzeFlu (Dymista ® , Meda, Sweden), comprising a formulation of an intranasal antihistamine (azelastine hydrochloride), an intranasal corticosteroid (fluticasone propionate), and excipients delivered in a single spray, may offer benefits over and above single and multiple AR therapy options. We review the evidence in support of this treatment across the spectrum of AR disease. The concept of AR control is also reviewed within the context of new European Union and Contre les Maladies Chroniques pour un VIeillissement Actif-Allergic Rhinitis and its Impact on Asthma initiatives.

AB - Allergic rhinitis (AR) poses a global health problem and can be challenging to treat. Many of the current symptomatic treatments for AR have been available for decades, yet there has been little improvement in patient quality of life or symptom burden over the years. In this review, we ask why this might be and explore the pathophysiological gaps that exist within the various AR treatment classes. We focus on the benefits and drawbacks of different treatment options and delivery routes for AR treatments and consider how, given what is known about AR pathophysiology and symptomatology, patients may be offered more effective treatment options for rapid, effective, and sustained AR control. In particular, we consider how a new AR preparation, MP-AzeFlu (Dymista ® , Meda, Sweden), comprising a formulation of an intranasal antihistamine (azelastine hydrochloride), an intranasal corticosteroid (fluticasone propionate), and excipients delivered in a single spray, may offer benefits over and above single and multiple AR therapy options. We review the evidence in support of this treatment across the spectrum of AR disease. The concept of AR control is also reviewed within the context of new European Union and Contre les Maladies Chroniques pour un VIeillissement Actif-Allergic Rhinitis and its Impact on Asthma initiatives.

KW - Allergic rhinitis

KW - Azelastine

KW - Fluticasone

KW - MP-AzeFlu

U2 - 10.1186/s13223-018-0314-1

DO - 10.1186/s13223-018-0314-1

M3 - Review article

VL - 15

JO - Allergy, Asthma and Clinical Immunology

JF - Allergy, Asthma and Clinical Immunology

SN - 1710-1484

IS - 1

M1 - 24

ER -